FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1335-1341 October 24, 2002 Number 17 Next

	Full Text PDF PDA Full Text Editorial by Drazen, J. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Concerned about threats to the integrity of clinical trials in a research environment increasingly controlled by private interests, the International Committee of Medical Journal Editors (ICMJE) has issued revised guidelines for investigators' participation in the study design, access to data, and control over publication. It is unclear whether research conducted at academic institutions adheres to these new standards.

Methods From November 2001 through January 2002, we interviewed officials at U.S. medical schools about provisions in their institutions' agreements with industry sponsors of multicenter clinical trials. A subgroup of the respondents were also asked about coordinating-center agreements for such trials.

Results Of the 122 medical schools that are members of the Association of American Medical Colleges, 108 participated in the survey. The median number of site-level agreements executed per institution in the previous year was 103 (interquartile range, 50 to 210). Scores for compliance with a wide range of provisions — from ensuring that authors of reports on multicenter trials have access to all trial data (1 percent [interquartile range, 0 to 21]) to addressing the plan for data collection and monitoring (10 percent [interquartile range, 1 to 50]) — demonstrated limited adherence to the standards embodied in the new ICMJE guidelines. Scores for coordinating-center agreements were somewhat higher for most survey items.

Conclusions Academic institutions routinely engage in industry-sponsored research that fails to adhere to ICMJE guidelines regarding trial design, access to data, and publication rights. Our findings suggest that a reevaluation of the process of contracting for clinical research is urgently needed.

Source Information

From the Center for Clinical and Genetic Economics (K.A.S., D.M.S., J.W.T., K.P.W.), the Outcomes Research and Assessment Group (D.B.M.), Duke Clinical Research Institute (R.M.C.), and the Center for the Study of Medical Ethics and Humanities (J.S., L.A.D.), Duke University Medical Center; and the Duke University School of Law (L.A.D.) — all in Durham, N.C.

Address reprint requests to Dr. Schulman at the Center for Clinical and Genetic Economics, Duke Clinical Research Institute, P.O. Box 17969, Durham, NC 27715, or at kevin.schulman{at}duke.edu.

Full Text of this Article

Related Letters:

Clinical-Trial Agreements between Medical Schools and Industry
Novak J. W., Barnes M., Gallin K. E., Meyer R. E., Korn D., Schulman K. A., Seils D. M., Califf R. M.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:476-478, Jan 30, 2003. Correspondence

This article has been cited by other articles:

• Carroll, J. D., Carroll, E. P. (2009). Is patent foramen ovale closure indicated for migraine?: PFO Closure Is Not Indicated for Migraine: "Don't Shoot First, Ask Questions Later". Circ Cardiovasc Interv 2: 475-481 [Full Text]  
• Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., Schulman, K. A. (2009). Ethical and Scientific Implications of the Globalization of Clinical Research. NEJM 360: 816-823 [Full Text]  
• Perrin, R. S., Lopez, F. J G. (2008). Incremental Drug Treatment Cost in HIV-Positive Patients in Industry-Sponsored Clinical Trials. The Annals of Pharmacotherapy 42: 1586-1591 [Abstract] [Full Text]  
• Noble, J. H. Jr, Sharav, V. H. (2008). Protecting People With Decisional Impairments and Legal Incapacity Against Biomedical Research Abuse. Journal of Disability Policy Studies 18: 230-244 [Abstract]  
• Harrington, R. A., Hasselblad, V., Califf, R. M. (2008). Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?. J Am Coll Cardiol 51: 33-36 [Full Text]  
• Mello, M. M., Joffe, S. (2007). Compact versus Contract -- Industry Sponsors' Obligations to Their Research Subjects. NEJM 356: 2737-2743 [Full Text]  
• Criner, G. J. (2007). Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials. Proc Am Thorac Soc 4: 171-175 [Abstract] [Full Text]  
• Califf, R. M (2006). Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clin Trials 3: 496-502 [Abstract]  
• Jacobs, J. J., Galante, J. O., Mirza, S. K., Zdeblick, T. (2006). Symposium. Relationships with Industry: Critical for New Technology or an Unnecessary Evil?. JBJS 88: 1650-1663 [Full Text]  
• Gotzsche, P. C., Hrobjartsson, A., Johansen, H. K., Haahr, M. T., Altman, D. G., Chan, A.-W. (2006). Constraints on Publication Rights in Industry-Initiated Clinical Trials. JAMA 295: 1645-1646 [Full Text]  
• Halperin, S. A., Scheifele, D., Duval, B., Ward, B. (2005). Conforming to ICMJE principles. CMAJ 173: 1358-1359 [Full Text]  
• Sierles, F. S., Brodkey, A. C., Cleary, L. M., McCurdy, F. A., Mintz, M., Frank, J., Lynn, D. J., Chao, J., Morgenstern, B. Z., Shore, W., Woodard, J. L. (2005). Medical Students' Exposure to and Attitudes About Drug Company Interactions: A National Survey. JAMA 294: 1034-1042 [Abstract] [Full Text]  
• Neale, A. V., Schwartz, K. L., Bowman, M. A. (2005). Conflict of Interest: Can We Minimize Its Influence in the Biomedical Literature?. J Am Board Fam Med 18: 411-413 [Full Text]  
• Abramson, J., Starfield, B. (2005). The Effect of Conflict of Interest on Biomedical Research and Clinical Practice Guidelines: Can We Trust the Evidence in Evidence-Based Medicine?. J Am Board Fam Med 18: 414-418 [Full Text]  
• Mirowski, P., Van Horn, R. (2005). The Contract Research Organization and the Commercialization of Scientific Research. Social Studies of Science 35: 503-548 [Abstract]  
• Brodkey, A. C. (2005). The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem. Acad. Psychiatry 29: 222-229 [Abstract] [Full Text]  
• Steinbrook, R. (2005). Gag Clauses in Clinical-Trial Agreements. NEJM 352: 2160-2162 [Full Text]  
• Mello, M. M., Clarridge, B. R., Studdert, D. M. (2005). Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. NEJM 352: 2202-2210 [Abstract] [Full Text]  
• Holloway, R. G., French, J. A., Kanner, A., Gronseth, G., Krauss, G. L., French, J. A., Panayiotopoulos, C. P., Benbadis, S. R., Covanis, A., Dulac, O., Duncan, J. S., Eeg-Olofsson, O., Ferrie, C. D., Grunewald, R. A., Kasteleijn-Nolst Trenite, D. G.A., Koutroumanidis, M., Martinovic, Z., Newton, R. W., Parker, A. P. J., Salas-Puig, J., Sander, J. W., Shorvon, S., Watanabe, K., Whitehouse, W. P., Youroukos, S., French, J. A. (2005). Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 64: 172-174 [Full Text]  
• Lexchin, J. R (2005). Implications of Pharmaceutical Industry Funding on Clinical Research. The Annals of Pharmacotherapy 39: 194-197 [Abstract] [Full Text]  
• Armstrong, P. W., Newby, L. K., Granger, C. B., Lee, K. L., Simes, R. J., Van de Werf, F., White, H. D., Califf, R. M., for the Virtual Coordinating Centre for Global Col, (2004). Lessons Learned From a Clinical Trial. Circulation 110: 3610-3614 [Full Text]  
• Califf, R. M., Nissen, S. E., DeMaria, A. N., Ohman, E. M., Pitt, B., Willerson, J. T., Bilheimer, D. W., Cohn, J. N., Feigal, D. W. Jr, Hampson, L., Lorell, B. H., Pepine, C. J., Popp, R. L. (2004). Task force 2: Investigator participation in clinical research. J Am Coll Cardiol 44: 1729-1736 [Full Text]  
• Califf, R. M., Nissen, S. E., DeMaria, A. N., Ohman, E. M., Pitt, B., Willerson, J. T., Bilheimer, D. W., Cohn, J. N., Feigal, D. W. Jr, Hampson, L., Lorell, B. H., Pepine, C. J., Popp, R. L. (2004). Task Force 2: Investigator Participation in Clinical Research. Circulation 110: 2517-2524 [Full Text]  
• De Vries, R. (2004). How Can We Help? From "Sociology in" to "Sociology of" Bioethics. J Law Med Ethics 32: 279-292  
• Boyd, E. A., Lipton, S., Bero, L. A. (2004). Implementation Of Financial Disclosure Policies To Manage Conflicts Of Interest. Health Aff (Millwood) 23: 206-214 [Abstract] [Full Text]  
• Garland, E. J. (2004). Facing the evidence: antidepressant treatment in children and adolescents. CMAJ 170: 489-491 [Full Text]  
• Schafer, A (2004). Biomedical conflicts of interest: a defence of the sequestration thesis--learning from the cases of Nancy Olivieri and David Healy. J. Med. Ethics 30: 8-24 [Abstract] [Full Text]  
• DuVal, G (2004). Institutional ethics review of clinical study agreements. J. Med. Ethics 30: 30-34 [Abstract] [Full Text]  
• Nathan, D. G., Wilson, J. D. (2003). Clinical Research and the NIH -- A Report Card. NEJM 349: 1860-1865 [Full Text]  
• Califf, R. M. (2003). Supplement on Acute Coronary Syndromes: Introduction. Circulation 108: III-1-5 [Full Text]  
• Baird, P. (2003). Getting it right: industry sponsorship and medical research. CMAJ 168: 1267-1269 [Full Text]  
• Heinig, M. J. (2003). The "Price" of Information. J Hum Lact 19: 133-135  
• Bruce Fye, W. (2003). The power of clinical trials and guidelines,and the challenge of conflicts of interest. J Am Coll Cardiol 41: 1237-1242 [Full Text]  
• Bernstein, A. (2003). Toward effective Canadian public-private partnerships in health research. CMAJ 168: 288-289 [Full Text]  
• Novak, J. W., Barnes, M., Gallin, K. E., Meyer, R. E., Korn, D., Schulman, K. A., Seils, D. M., Califf, R. M. (2003). Clinical-Trial Agreements between Medical Schools and Industry. NEJM 348: 476-478 [Full Text]  
• Bekelman, J. E., Li, Y., Gross, C. P. (2003). Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review. JAMA 289: 454-465 [Abstract] [Full Text]  
• (2002). The controlling interests of research. CMAJ 167: 1221-1221 [Full Text]  
• (2002). Les interets qui controlent la recherche. CMAJ 167: 1223-1223 [Full Text]  
• Tanne, J. H. (2002). Better standards needed for industry sponsored clinical trials. BMJ 325: 985-985 [Full Text]  
• Drazen, J. M. (2002). Institutions, Contracts, and Academic Freedom. NEJM 347: 1362-1363 [Full Text]